A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
← catalyst calendarNCT07608354 · readout in 902 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
326estimated
Sites
76
Countries
Canada, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | actual | When the study began enrolling |
| Primary completion | 2029-02-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions
- Drug: Eplontersen
- Biological: ALXN2220
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFCardiopulmonary exercise test peak VO2
measured 52 week
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed